Navigation Links
Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
Date:5/4/2010

SCHAUMBURG, Ill. and MORRISTOWN, N.J., May 4 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, and Actavis Inc., a leading global generic pharmaceutical manufacturer, have launched an exclusive collaboration to develop and market a select group of specialty injectable medications for the United States.

Under the agreement, Actavis will develop, obtain U.S. Food and Drug Administration approval, and supply the products, which Sagent will market in the United States. Financial terms of the agreement have not been disclosed.

"Actavis' impressive injectable pipeline, substantial development and supply capabilities and excellent record of execution make Actavis an outstanding partner for Sagent," said Jeffrey M. Yordon, Sagent's chief executive officer, founder and chairman of the board. "This collaboration complements Sagent's strategy by quickly adding products to our marketed portfolio and we look forward to working with Actavis to expand our collective portfolio."

Doug Boothe, chief executive officer of Actavis Inc., said the strategic collaboration with Sagent will enable consumers in the United States to benefit from the company's global expertise in developing and manufacturing specialty injectable products.

"By combining our injectable pipeline with Sagent's and partnering with their sales and marketing team, we have increased our potential to serve the U.S. market for these valuable products beyond what either of our companies could have achieved independently," Boothe said. Headquartered in Morristown, N.J., Actavis Inc. is the U.S. subsidiary of Iceland-based Actavis Group.  

About Sagent Pharmaceuticals

Sagent Pharmaceuticals is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.  Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients.

To Discover Injectables Excellence™ and learn more about Sagent, please visit www.SagentPharma.com.

About Actavis Inc.

Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one quarter of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing facilities in Elizabeth, NJ; Little Falls, NJ; Totowa, NJ; and Lincolnton, NC. Actavis also has research and development facilities in Owings Mills, MD and Sunrise, FL; and a packaging facility in Totowa, NJ. Please visit www.actavis.us for more information.


'/>"/>
SOURCE Sagent Pharmaceuticals, Inc.; Actavis Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces U.S. FDA Tentative Approval of Additional Adenosine Injection, USP Vial Presentations
2. Sagent Pharmaceuticals Announces FDA Approval of Labetalol Hydrochloride Injection, USP
3. Sagent Pharmaceuticals Launches Pamidronate Disodium Injection
4. Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches
5. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
6. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
7. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
8. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
9. Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
10. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
11. ISTA Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... -- Halyard Health, Inc. (NYSE: HYH ) today ... 2017 outlook and related key planning assumptions. Executive Summary ... 2 percent increase compared to the prior year. ... million compared to net income of $15 million in the ... $24 million compared to adjusted net income of $27 million ...
(Date:2/27/2017)... , Feb. 27, 2017 Mederi Therapeutics ... 28 studies, representing 2468 patients who received  Stretta ... study entitled, " Systematic Review and Meta-Analysis of ... Radiofrequency for Treatment of Gastroesophageal Reflux Disease ", was ... Ronnie Fass , MD, head of the ...
(Date:2/27/2017)... AMSTERDAM , Feb. 27, 2017   ... AEX: PHIA), a global leader in health technology, ... and Drug Administration (FDA) to market its ElastQ ... EPIQ family of ultrasound systems. ElastQ Imaging enables ... stiffness, which is essential for the diagnosis of ...
Breaking Medicine Technology:
(Date:2/28/2017)... Los Angeles, CA (PRWEB) , ... February 28, 2017 , ... ... prostate cancer and vasectomies. In studying approximately 800 deaths from prostate cancer, the researchers ... prostate cancer and 20% more likely to get fatal prostate cancer. Although the increased ...
(Date:2/28/2017)... ... February 28, 2017 , ... TruClinic Inc. ... intelligence company based in New York. , “Ensuring an intuitive, user-friendly patient experience ... unaltered. Those two fundamental reasons are the reasons this acquisition is an obvious ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... 2017, from 4:30-5:30 p.m. at the 11th Annual RISE Nashville Summit. RISE Nashville ... compliance, performance analytics, and engagement strategies. , The discussion will include best practices ...
(Date:2/27/2017)... ... February 27, 2017 , ... Hotze Health ... announces Chris Brandl as its New Guest Director. , Brandl is a ... throughout his career. He began his professional career at Omnium Worldwide, now known ...
(Date:2/27/2017)... PORT RICHEY, Fla. (PRWEB) , ... February 27, 2017 , ... ... use disorder, but concern for women who become dependent on opioid painkillers has fallen ... among female patients, compared to a 237% increase in fatal overdoses in male populations.(1) ...
Breaking Medicine News(10 mins):